Transcutaneous-Arterial Carbon Dioxide and Microcirculatory Dysfunction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02328846|
Recruitment Status : Withdrawn (Insufficient equipment)
First Posted : December 31, 2014
Last Update Posted : October 22, 2018
Evaluation of the microcirculation is currently limited. Continual assessment of the tissue carbon dioxide-arterial carbon dioxide (PtC02-aCO2) offers a new, novel and noninvasive method of determining the state of the microcirculation. The investigators will apply two non-invasive devices, the Braedius sidesteam darkfield microscopy (SDF) microscopy device to the sublingual circulation and the transcutaneous PtC02 probe to the forehead in subjects undergoing cardiac surgery with cardiopulmonary bypass. The PtC02-aCO2 gradient will be determined and correlated with the videomicroscopic images of the sublingual microcirculation. Thereafter the incidence of postoperative organ failure and acute kidney injury will be determined and correlated with PtC02-arterial CO2 gradient and videomicroscopic images.
Data will be analyzed by standard descriptive statistical methods.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Transcutaneous-Arterial Carbon Dioxide Gradient Predicts Microcirculatory Dysfunction And The Development of Organ Failure After Cardiac Surgery|
|Estimated Study Start Date :||January 2018|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||February 2020|
- Postoperative SOFA score [ Time Frame: Participants will be followed for the duration of ICU stay, an expected average of 1 weeks ]
- Postoperative Kidney Disease Improving Global Outcome (KDIGO) class [ Time Frame: Participants will be followed for the duration of ICU stay, an expected average of 1 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02328846
|Principal Investigator:||Bhiken I Naik, M.B.B.Ch||University of Virginia|